Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

2.

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM.

RMD Open. 2019 Jan 22;5(1):e000836. doi: 10.1136/rmdopen-2018-000836. eCollection 2019.

3.

Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).

Putrik P, Ramiro S, Moltó A, Keszei AP, Norton S, Dougados M, van der Heijde D, Landewé RBM, Boonen A.

Ann Rheum Dis. 2019 Apr;78(4):486-493. doi: 10.1136/annrheumdis-2018-214259. Epub 2019 Jan 23.

PMID:
30674477
4.

Response to: 'Catching the falling star: points to consider when using propensity scores' by Ouyang et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Dec 30. pii: annrheumdis-2018-214892. doi: 10.1136/annrheumdis-2018-214892. [Epub ahead of print] No abstract available.

PMID:
30598466
5.

Response to: 'Metering the METEOR in methotrexate failure: is propensity score a falling star?' by Ahmed et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Nov 14. pii: annrheumdis-2018-214652. doi: 10.1136/annrheumdis-2018-214652. [Epub ahead of print] No abstract available.

PMID:
30429121
6.

How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.

Bergstra SA, Winchow LL, Murphy E, Chopra A, Salomon-Escoto K, Fonseca JE, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2019 Jan;78(1):25-30. doi: 10.1136/annrheumdis-2018-213731. Epub 2018 Oct 16.

PMID:
30327328
7.

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort.

Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landewé RBM, Dagfinrud H, Jacobsson LTH, van der Heijde D, van Gaalen FA.

Arthritis Res Ther. 2018 Oct 1;20(1):218. doi: 10.1186/s13075-018-1705-x.

8.

Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis.

Bautista-Molano W, Landewé RBM, Kiltz U, Valle-Oñate R, van der Heijde D.

Clin Rheumatol. 2018 Nov;37(11):3063-3068. doi: 10.1007/s10067-018-4308-7. Epub 2018 Sep 26.

PMID:
30259248
9.

Response to: 'Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis' by Ferreira et al.

Landewé RBM.

Ann Rheum Dis. 2018 Aug 20. pii: annrheumdis-2018-214221. doi: 10.1136/annrheumdis-2018-214221. [Epub ahead of print] No abstract available.

PMID:
30127057
10.

Response to: 'Early identification of rheumatoid arthritis; the risk of overtreatment in perspective' by Landewé.

Landewé RBM.

Ann Rheum Dis. 2018 Aug 10. pii: annrheumdis-2018-214172. doi: 10.1136/annrheumdis-2018-214172. [Epub ahead of print] No abstract available.

PMID:
30097455
11.

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1413-1420. doi: 10.1136/annrheumdis-2018-213289. Epub 2018 Jul 6.

PMID:
29980576
12.

Overdiagnosis and overtreatment in rheumatology: a little caution is in order.

Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1394-1396. doi: 10.1136/annrheumdis-2018-213700. Epub 2018 Jul 4. Review.

PMID:
29973350
13.

Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.

Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, Murphy EA, Landewé RBM.

J Rheumatol. 2018 Oct;45(10):1361-1366. doi: 10.3899/jrheum.171176. Epub 2018 Jun 15.

PMID:
29907672
14.

Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.

Rodrigues Manica S, Sepriano A, Ramiro S, Pimentel Santos F, Putrik P, Nikiphorou E, Norton S, Molto A, Dougados M, van der Heijde D, Landewé RBM, van den Bosch FE, Boonen A.

Ann Rheum Dis. 2018 Sep;77(9):1303-1310. doi: 10.1136/annrheumdis-2018-213464. Epub 2018 Jun 2.

PMID:
29860232
15.

"Big Data" in Rheumatology: Intelligent Data Modeling Improves the Quality of Imaging Data.

Landewé RBM, van der Heijde D.

Rheum Dis Clin North Am. 2018 May;44(2):307-315. doi: 10.1016/j.rdc.2018.01.007. Review.

PMID:
29622297
16.

Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.

Boeters DM, Nieuwenhuis WP, van Steenbergen HW, Reijnierse M, Landewé RBM, van der Helm-van Mil AHM.

Ann Rheum Dis. 2018 Jun;77(6):861-868. doi: 10.1136/annrheumdis-2017-212252. Epub 2018 Feb 28.

17.

The nocebo effect challenges the non-medical infliximab switch in practice.

Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA.

Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24.

18.

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.

van der Heijde D, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J.

Ann Rheum Dis. 2018 May;77(5):699-705. doi: 10.1136/annrheumdis-2017-212377. Epub 2018 Jan 17.

19.

Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.

Nikiphorou E, van der Heijde D, Norton S, Landewé RB, Molto A, Dougados M, Van den Bosch FE, Ramiro S.

Ann Rheum Dis. 2018 Mar;77(3):405-411. doi: 10.1136/annrheumdis-2017-212457. Epub 2017 Dec 8.

PMID:
29222349
20.

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM.

Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.

21.

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS.

Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu J, Wei JCC, Dougados M; ASAS-FLARE study group.

Ann Rheum Dis. 2018 Jan;77(1):124-127. doi: 10.1136/annrheumdis-2017-212178. Epub 2017 Oct 16.

PMID:
29038299
22.

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.

Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D.

Ann Rheum Dis. 2018 Feb;77(2):221-227. doi: 10.1136/annrheumdis-2017-212008. Epub 2017 Sep 29.

23.

Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

Burgers LE, Siljehult F, Ten Brinck RM, van Steenbergen HW, Landewé RBM, Rantapää-Dahlqvist S, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2017 Dec 1;56(12):2123-2128. doi: 10.1093/rheumatology/kex324.

PMID:
28968699
24.

Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.

Bergstra SA, Olivas O, Akdemir G, Riyazi N, Collée G, van Groenendael JHLM, Landewé RBM, Allaart CF.

Arthritis Res Ther. 2017 Sep 30;19(1):220. doi: 10.1186/s13075-017-1425-7.

25.

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.

Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF.

Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

PMID:
28957556
26.

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.

Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.

Ann Rheum Dis. 2018 Jan;77(1):63-69. doi: 10.1136/annrheumdis-2017-211544. Epub 2017 Sep 22.

27.

Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort.

Ez-Zaitouni Z, Landewé RBM, van der Heijde D, van Gaalen FA.

Ann Rheum Dis. 2018 Jun;77(6):e34. doi: 10.1136/annrheumdis-2017-212175. Epub 2017 Aug 22. No abstract available.

PMID:
28830880
28.

Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al.

Ramiro S, Smolen JS, Landewé RBM, van der Heijde D, Gossec L.

Ann Rheum Dis. 2018 May;77(5):e24. doi: 10.1136/annrheumdis-2017-212012. Epub 2017 Aug 16. No abstract available.

PMID:
28814427
29.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

30.

The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts.

Ez-Zaitouni Z, Bakker PA, van Lunteren M, de Hooge M, van den Berg R, Reijnierse M, Fagerli KM, Landewé RB, Ramonda R, Jacobsson LT, Saraux A, Lenczner G, Feydy A, Pialat JB, Thévenin F, van Gaalen FA, van der Heijde D.

Ann Rheum Dis. 2017 Oct;76(10):1731-1736. doi: 10.1136/annrheumdis-2017-211486. Epub 2017 Jun 29.

PMID:
28663306
31.

Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al.

Smolen JS, Landewé RBM, van der Heijde D.

Ann Rheum Dis. 2017 Nov;76(11):e48. doi: 10.1136/annrheumdis-2017-211455. Epub 2017 May 6. No abstract available.

PMID:
28478402
32.

Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirilä et al.

Smolen JS, Landewé RBM, van der Heijde D.

Ann Rheum Dis. 2017 Dec;76(12):e50. doi: 10.1136/annrheumdis-2017-211524. Epub 2017 Apr 27. No abstract available.

PMID:
28450310
33.

The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort.

Ez-Zaitouni Z, van Lunteren M, Bakker PAC, van den Berg R, Reijnierse M, Fagerli KM, Landewé RBM, Ramonda R, Jacobsson LTH, van Gaalen FA, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):e1. doi: 10.1136/annrheumdis-2017-211553. Epub 2017 Apr 17. No abstract available.

PMID:
28416518
34.

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

Bouman CA, den Broeder AA, van der Maas A, van den Hoogen FH, Landewé RB, van Herwaarden N.

RMD Open. 2017 Mar 20;3(1):e000327. doi: 10.1136/rmdopen-2016-000327. eCollection 2017.

35.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
36.

Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.

Bergstra SA, Allaart CF, Stijnen T, Landewé RBM.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1473-1483. doi: 10.1002/acr.23164. Epub 2017 Aug 31. Review.

37.

Why CAPS criteria are not diagnostic criteria?

Landewé RB, van der Heijde DM.

Ann Rheum Dis. 2017 Apr;76(4):e7. doi: 10.1136/annrheumdis-2016-210656. Epub 2016 Oct 31. No abstract available.

PMID:
27799158
38.
39.

Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives.

Bergstra SA, Machado PM, van den Berg R, Landewé RB, Huizinga TW.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S87-S90. Epub 2016 Oct 19. Review.

40.

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.

Landewé RB, Connell CA, Bradley JD, Wilkinson B, Gruben D, Strengholt S, van der Heijde D.

Arthritis Res Ther. 2016 Sep 23;18(1):212.

41.

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofu S.

Arthritis Rheumatol. 2016 Aug;68(8):1914-21. doi: 10.1002/art.39685.

42.

Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review.

Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D.

J Rheumatol. 2016 Mar;43(3):607-17. doi: 10.3899/jrheum.150721. Epub 2016 Feb 1. Review.

PMID:
26834216
43.

Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis.

Bautista-Molano W, Landewé RB, Londoño J, Romero-Sanchez C, Valle-Oñate R, van der Heijde D.

Clin Rheumatol. 2016 Jul;35(7):1759-67. doi: 10.1007/s10067-016-3184-2. Epub 2016 Jan 21.

PMID:
26791876
44.

Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis.

Bergstra SA, Markusse IM, Akdemir G, Ronday HK, Han KH, Lems WF, Kerstens PJSM, van den Berg R, Landewé RBM, Allaart CF.

Clin Rheumatol. 2016 Aug;35(8):2101-2107. doi: 10.1007/s10067-015-3145-1. Epub 2015 Dec 22.

45.

Cardiovascular Morbidity and Mortality Among Working Individuals With Rheumatic Disease: Results From a Large Prospective Cohort Study.

van der Burg LR, van Amelsvoort LG, Boonen A, Jansen N, Kant IJ, Landewé RB.

J Clin Rheumatol. 2015 Oct;21(7):359-63. doi: 10.1097/RHU.0000000000000294.

PMID:
26398463
46.

Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.

Gvozdenović E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB.

J Clin Rheumatol. 2015 Oct;21(7):349-54. doi: 10.1097/RHU.0000000000000296.

PMID:
26398461
47.

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs).

Boone NW, Teeuwisse P, van der Kuy PH, Janknegt R, Landewé RB.

Springerplus. 2015 Aug 28;4:462. doi: 10.1186/s40064-015-1247-5. eCollection 2015.

48.

Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D.

Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi: 10.1002/14651858.CD010952.pub2. Review.

PMID:
26186173
49.

Single-joint Assessment for the Evaluation of Intraarticular Treatment: Responsiveness and Discrimination of the Composite Change Index.

Aalbers CJ, Gerlag DM, Vervoordeldonk MJ, Tak PP, Landewé RB.

J Rheumatol. 2015 Sep;42(9):1672-6. doi: 10.3899/jrheum.140956. Epub 2015 Jul 15.

PMID:
26178282
50.

Nonsteroidal anti-inflammatory drugs for treatment of acute gout.

van Durme CM, Wechalekar MD, Landewé RB.

JAMA. 2015 Jun 9;313(22):2276-7. doi: 10.1001/jama.2015.1881.

PMID:
26057289

Supplemental Content

Loading ...
Support Center